Circulating microRNAs as promising diagnostic biomarkers for pancreatic cancer: a systematic review

: Pancreatic cancer (PC) is one of the most common forms of malignant tumors and causes of tumor-related death worldwide. The current prognosis of PC still remains poor due to the lack of effective early detection method. Recently, there is strong support that circulating miRNAs can be used as biomarkers for early detection of various cancers, including PC. The purpose of this review is to provide an overview of previous published studies on circulating miRNAs in plasma/serum for early detection of PC and summarize their diagnostic value. PubMed, Embase and Web of Science were systematically searched for eligible studies on circulating miRNAs for PC detection. Overall, 29 studies published between 2009 and 2018 evaluating 51 individual miRNAs (no P -value exceeding 0.05) and 13 miRNAs panels were included. Generally, the diagnostic performance of circulating miRNAs for PC detection was strong, with both the sensitivity and speci fi city of 36% individual miRNAs and 40% miRNAs panels exceeding 80%. Moreover, two promising miRNA panels were discovered and veri fi ed externally with all AUC values exceeding 0.95. Therefore, circulating miRNAs may hold potential to be used as noninvasive diagnostic biomarkers for PC, but large-scale studies are still needed to validate the promising miRNAs and optimize the miRNA panels. Since, the tremendous heterogeneity of studies in this fi eld hampers translating miRNA markers into clinical practice, miRNA analytical procedures are also needed to be standardized in the future.

[1]  W. Yuan,et al.  Corrigendum to “Evaluation of Plasma MicroRNAs as Diagnostic and Prognostic Biomarkers in Pancreatic Adenocarcinoma: miR-196a and miR-210 Could Be Negative and Positive Prognostic Markers, Respectively” , 2018, BioMed research international.

[2]  Han Liu,et al.  MicroRNA-221-3p is up-regulated and serves as a potential biomarker in pancreatic cancer , 2018, Artificial cells, nanomedicine, and biotechnology.

[3]  T. Okumura,et al.  An elevated expression of serum exosomal microRNA-191, − 21, −451a of pancreatic neoplasm is considered to be efficient diagnostic marker , 2018, BMC Cancer.

[4]  Elliot K Fishman,et al.  Diagnosis and Detection of Pancreatic Cancer , 2017, Cancer journal.

[5]  P. Vineis,et al.  Plasma microRNAs as biomarkers of pancreatic cancer risk in a prospective cohort study , 2017, International journal of cancer.

[6]  R. Postier,et al.  Plasma exosome miR-196a and miR-1246 are potential indicators of localized pancreatic cancer , 2017, Oncotarget.

[7]  D. Ichikawa,et al.  Depleted tumor suppressor miR-107 in plasma relates to tumor progression and is a novel therapeutic target in pancreatic cancer , 2017, Scientific Reports.

[8]  Ke Li,et al.  Circulating miRNA-21-5p as a diagnostic biomarker for pancreatic cancer: evidence from comprehensive miRNA expression profiling analysis and clinical validation , 2017, Scientific Reports.

[9]  H. Chang,et al.  Application values of detection of serum CA199, CA242 and CA50 in the diagnosis of pancreatic cancer. , 2017, Journal of biological regulators and homeostatic agents.

[10]  S. Hanash,et al.  High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  Xianyin Lai,et al.  A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer , 2017, Cancer letters.

[12]  Henrik Antti,et al.  Plasma Micro-RNA Alterations Appear Late in Pancreatic Cancer , 2017, Annals of surgery.

[13]  S. Bojesen,et al.  The potential diagnostic value of serum microRNA signature in patients with pancreatic cancer , 2016, International journal of cancer.

[14]  Y. Qiao,et al.  New combined microRNA and protein plasmatic biomarker panel for pancreatic cancer , 2016, Oncotarget.

[15]  Bolin Sun,et al.  Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients , 2016, British journal of biomedical science.

[16]  R. Liu,et al.  Identification of Circulating MiR-25 as a Potential Biomarker for Pancreatic Cancer Diagnosis , 2016, Cellular Physiology and Biochemistry.

[17]  B. Su,et al.  Identification of serum miRNAs by nano-quantum dots microarray as diagnostic biomarkers for early detection of non-small cell lung cancer , 2016, Tumor Biology.

[18]  Y. Miao,et al.  Plasma miRNAs Effectively Distinguish Patients With Pancreatic Cancer From Controls: A Multicenter Study , 2016, Annals of surgery.

[19]  Zhuiyang Zhang,et al.  Presurgical Evaluation of Pancreatic Cancer: A Comprehensive Imaging Comparison of CT Versus MRI. , 2016, AJR. American journal of roentgenology.

[20]  P. Ashton-Prolla,et al.  miRNA-21 and miRNA-34a Are Potential Minimally Invasive Biomarkers for the Diagnosis of Pancreatic Ductal Adenocarcinoma , 2016, Pancreas.

[21]  Fudong Yu,et al.  Combined detection of preoperative serum CEA, CA19-9 and CA242 improve prognostic prediction of surgically treated colorectal cancer patients. , 2015, International journal of clinical and experimental pathology.

[22]  D. Ichikawa,et al.  Plasma microRNA profiles: identification of miR-744 as a novel diagnostic and prognostic biomarker in pancreatic cancer , 2015, British Journal of Cancer.

[23]  D. Ichikawa,et al.  Malignant potential in pancreatic neoplasm: new insights provided by circulating mir-223 in plasma , 2015 .

[24]  R. Scharpf,et al.  Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients , 2015, Nature Communications.

[25]  Motohiro Kojima,et al.  MicroRNA Markers for the Diagnosis of Pancreatic and Biliary-Tract Cancers , 2015, PloS one.

[26]  Heng-jun Gao,et al.  Aberrant expression of microRNAs in serum may identify individuals with pancreatic cancer. , 2014, International journal of clinical and experimental medicine.

[27]  N. Tanaka,et al.  Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer , 2014, International journal of oncology.

[28]  Hailong Xie,et al.  U6 is not a suitable endogenous control for the quantification of circulating microRNAs. , 2014, Biochemical and biophysical research communications.

[29]  J. Bae.  An overview of systematic reviews of diagnostic tests accuracy , 2014, Epidemiology and health.

[30]  K. Strauch,et al.  MicroRNA-196a and -196b as Potential Biomarkers for the Early Detection of Familial Pancreatic Cancer , 2014, Translational oncology.

[31]  Benjamin D. Smith,et al.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.

[32]  Min Shi,et al.  Upregulation of miR-194 contributes to tumor growth and progression in pancreatic ductal adenocarcinoma. , 2014, Oncology reports.

[33]  G. A. Ganepola,et al.  Novel blood-based microRNA biomarker panel for early diagnosis of pancreatic cancer. , 2014, World journal of gastrointestinal oncology.

[34]  Nathalie Zahra,et al.  Influence of Plasma Processing on Recovery and Analysis of Circulating Nucleic Acids , 2013, PloS one.

[35]  U. Ballehaninna,et al.  Biomarkers for pancreatic cancer: promising new markers and options beyond CA 19-9 , 2013, Tumor Biology.

[36]  Jian Gu,et al.  Pathway-based serum microRNA profiling and survival in patients with advanced stage non-small cell lung cancer. , 2013, Cancer research.

[37]  C. Lockwood,et al.  Pre-analytical variables in miRNA analysis. , 2013, Clinical biochemistry.

[38]  Min Shi,et al.  Diagnostic and biological significance of microRNA-192 in pancreatic ductal adenocarcinoma. , 2013, Oncology reports.

[39]  R. Hruban,et al.  MicroRNA Array Analysis Finds Elevated Serum miR-1290 Accurately Distinguishes Patients with Low-Stage Pancreatic Cancer from Healthy and Disease Controls , 2013, Clinical Cancer Research.

[40]  L. Paz-Ares,et al.  DICER1, DROSHA and miRNAs in patients with non-small cell lung cancer: implications for outcomes and histologic classification. , 2013, Carcinogenesis.

[41]  D. Ichikawa,et al.  Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer , 2013, British Journal of Cancer.

[42]  Y. Li,et al.  Method for microRNA isolation from clinical serum samples. , 2012, Analytical biochemistry.

[43]  H. Döhner,et al.  Impact of serum storage conditions on microRNA stability , 2012, Leukemia.

[44]  Y. Gong,et al.  Combination of plasma microRNAs with serum CA19‐9 for early detection of pancreatic cancer , 2012, International journal of cancer.

[45]  R. Qi,et al.  Identification of endogenous normalizers for serum MicroRNAs by microarray profiling: U6 small nuclear RNA is not a reliable normalizer , 2012, Hepatology.

[46]  Lihua He,et al.  Changes in the expression of serum markers CA242, CA199, CA125, CEA, TNF-α and TSGF after cryosurgery in pancreatic cancer patients , 2012, Biotechnology Letters.

[47]  C. Croce,et al.  MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review , 2012, EMBO molecular medicine.

[48]  Xi Chen,et al.  Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. , 2012, Clinical chemistry.

[49]  D. Ichikawa,et al.  Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer , 2011, British Journal of Cancer.

[50]  Susan Mallett,et al.  Circulating MicroRNAs as a Novel Class of Diagnostic Biomarkers in Gastrointestinal Tumors Detection: A Meta-Analysis Based on 42 Articles , 2014, PloS one.

[51]  F. Marabita,et al.  Distinct microRNA signatures in human lymphocyte subsets and enforcement of the naive state in CD4+ T cells by the microRNA miR-125b , 2011, Nature Immunology.

[52]  Keith W. Jones,et al.  Impact of Cellular miRNAs on Circulating miRNA Biomarker Signatures , 2011, PloS one.

[53]  Alicia Algeciras-Schimnich,et al.  Analysis of circulating microRNA: preanalytical and analytical challenges. , 2011, Clinical chemistry.

[54]  Jessica A. Weber,et al.  The microRNA spectrum in 12 body fluids. , 2010, Clinical chemistry.

[55]  Allen D. Delaney,et al.  Comprehensive microRNA expression profiling of the hematopoietic hierarchy , 2010, Proceedings of the National Academy of Sciences.

[56]  C. Atreya,et al.  Differential profiling of human red blood cells during storage for 52 selected microRNAs , 2010, Transfusion.

[57]  J. Weinstein,et al.  mRNA and microRNA Expression Profiles of the NCI-60 Integrated with Drug Activities , 2010, Molecular Cancer Therapeutics.

[58]  Tibor Schuster,et al.  Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages , 2010, PLoS medicine.

[59]  Muneesh Tewari,et al.  Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). , 2010, Methods.

[60]  Ann M. Killary,et al.  MicroRNAs in Plasma of Pancreatic Ductal Adenocarcinoma Patients as Novel Blood-Based Biomarkers of Disease , 2009, Cancer Prevention Research.

[61]  X. Chen,et al.  Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases , 2008, Cell Research.

[62]  Yariv Yogev,et al.  Serum MicroRNAs Are Promising Novel Biomarkers , 2008, PloS one.

[63]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[64]  William C Reinhold,et al.  MicroRNAs modulate the chemosensitivity of tumor cells , 2008, Molecular Cancer Therapeutics.

[65]  C. Benz,et al.  Rapid alteration of microRNA levels by histone deacetylase inhibition. , 2006, Cancer research.

[66]  Young Jun Kim,et al.  Pancreatic and peripancreatic diseases mimicking primary pancreatic neoplasia. , 2005, Radiographics : a review publication of the Radiological Society of North America, Inc.

[67]  R. Jeffrey,et al.  Isoattenuating pancreatic adenocarcinoma at multi-detector row CT: secondary signs. , 2002, Radiology.

[68]  T. Tuschl,et al.  Identification of Novel Genes Coding for Small Expressed RNAs , 2001, Science.

[69]  Kenneth J. Chang,et al.  Endosonography-guided fine-needle aspiration biopsy: diagnostic accuracy and complication assessment. , 1997, Gastroenterology.

[70]  Y. Chung,et al.  Evaluation of serum pancreatic enzymes, carbohydrate antigen 19-9, and carcinoembryonic antigen in various pancreatic diseases. , 1985, The American journal of gastroenterology.

[71]  Zhen Chen,et al.  Low serum miR-373 predicts poor prognosis in patients with pancreatic cancer. , 2017, Cancer biomarkers : section A of Disease markers.

[72]  Neveen Abd El Moneim Hussein,et al.  Plasma miR-22-3p, miR-642b-3p and miR-885-5p as diagnostic biomarkers for pancreatic cancer , 2016, Journal of Cancer Research and Clinical Oncology.

[73]  Honghe Zhang,et al.  Tumor markers CA 19-9 , CA 242 and CEA in the diagnosis of pancreatic cancer : a meta-analysis , 2015 .

[74]  Joon Cheol Park,et al.  Plasma components affect accuracy of circulating cancer-related microRNA quantitation. , 2012, The Journal of molecular diagnostics : JMD.

[75]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.